Please assess the completion status of the following clinical trial:

Trial Title: Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
All candidates must have previously untreated hypertension. The candidates will be picked from patients with stage-1 hypertension (systolic BP 140-159 mm Hg or diastolic BP 90-99 mm Hg) and those with stage-2 hypertension (systolic BP ≥160 mm Hg or diastolic BP ≥100), based on the seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines (JNC-7).~Inclusion Criteria:~* Presence of inappropriate LVM.~* Presence of phenotype of inappropriate LVM.~Exclusion Criteria:~The criteria will assure that only patients with hypertension are enrolled, that is, excluded will be subjects with systolic BP \< 140 or diastolic BP \< 90 (ie, prehypertension or normal BP), but without complications or any indication (or suspicion) of end-organ damage based on a physical exam, clinical history, or laboratory tests.~Specific exclusion criteria are:~* Reactive airways disease including asthma.~* Diabetes mellitus or hypoglycemia; thyrotoxicosis.~* LV dysfunction (ejection fraction \< 50%) or heart failure.~* Present or previously documented coronary heart disease or angina.~* Acute myocardial infarction, or history of myocardial infarction.~* Severe bradycardia, heart block greater than first degree or sick sinus syndrome (unless a permanent pacemaker is in place).~* Hepatic insufficiency or history of cirrhosis.~* Chronic renal failure or renovascular dysfunction.~* Cerebrovascular dysfunction.~* Peripheral vascular disease.~* Pregnant or nursing women; women of childbearing age will be required to take a pregnancy test at the time of enrollment and use an acceptable method of birth control.~* Poor echo image quality.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Nebivolol (Type: EXPERIMENTAL): Subjects randomized to this arm will receive Nebivolol 2.5 mg once daily.
- Metoprolol succinate (Type: OTHER): Subjects randomized to this arm will receive metoprolol succinate 50 mg once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).